Annovis Bio Inc.

11.27+0.3900+3.58%Vol 46.84K1Y Perf -86.39%
Jun 24th, 2022 16:00 DELAYED
BID10.00 ASK12.89
Open11.14 Previous Close10.88
Pre-Market- After-Market-
 - -  - -%
Target Price
31.50 
Analyst Rating
Strong Buy 1.00
Potential %
179.50 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
2.33 
Earnings Rating
Market Cap92.00M 
Earnings Date
27th Jul 2022
Alpha0.06 Standard Deviation0.45
Beta2.12 

Today's Price Range

10.9611.85

52W Range

8.39132.00

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
5.43%
1 Month
26.06%
3 Months
-19.50%
6 Months
-45.45%
1 Year
-86.39%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ANVS11.270.39003.58
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022--0.72-
Q03 2021--0.35-
Q02 2020--0.34-
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date27th Jul 2022
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume46.84K
Shares Outstanding8.16K
Shares Float5.64M
Trades Count757
Dollar Volume532.59K
Avg. Volume39.90K
Avg. Weekly Volume31.98K
Avg. Monthly Volume47.79K
Avg. Quarterly Volume39.94K

Annovis Bio Inc. (AMEX: ANVS) stock closed at 11.27 per share at the end of the most recent trading day (a 3.58% change compared to the prior day closing price) with a volume of 46.84K shares and market capitalization of 92.00M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 2 people. Annovis Bio Inc. CEO is Maria Maccecchini.

The one-year performance of Annovis Bio Inc. stock is -86.39%, while year-to-date (YTD) performance is -35.89%. ANVS stock has a five-year performance of %. Its 52-week range is between 8.385 and 132, which gives ANVS stock a 52-week price range ratio of 2.33%

Annovis Bio Inc. currently has a PE ratio of -4.90, a price-to-book (PB) ratio of 2.08, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -69.76%, a ROC of -74.19% and a ROE of -74.05%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Annovis Bio Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Annovis Bio Inc.’s next earnings report date is 27th Jul 2022.

The consensus rating of Wall Street analysts for Annovis Bio Inc. is Strong Buy (1), with a target price of $31.5, which is +179.50% compared to the current price. The earnings rating for Annovis Bio Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Annovis Bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Annovis Bio Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 36.41, ATR14 : 1.14, CCI20 : 67.79, Chaikin Money Flow : -0.04, MACD : 0.09, Money Flow Index : 52.36, ROC : 4.35, RSI : 53.96, STOCH (14,3) : 36.59, STOCH RSI : 1.00, UO : 45.49, Williams %R : -63.41), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Annovis Bio Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Annovis Bio Inc.

Annovis Bio Inc is a clinical stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neuro degenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.

CEO: Maria Maccecchini

Telephone: +1 610 727-3913

Address: 1055 Westlakes Drive, Berwyn 19312, PA, US

Number of employees: 2

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

67%33%

Bearish Bullish

63%37%

News

Stocktwits